Patterns of immune-related adverse events in patients treated for various cancer types with immune checkpoint inhibitors
Primary cancer type was not significantly associated with tissue-specific irAEs in ICI-treated patients. The 5.58-month difference in median time to irAE onset has important implications for monitoring protocols. Further research is needed to identify factors predicting irAE patterns and severity.
Authors
- Gianna Kroening
- Armon Azizi (ORCID: https://orcid.org/0000-0002-1353-2060)
- Matthew Slaught
- Dalia Kaakour (ORCID: https://orcid.org/0000-0003-2985-9591)
- Jennifer B. Valerin
- Nataliya Mar
- Wen-Pin Chen
Institutions
- University of California, Irvine (US)
- University of California System (US)
- Cancer Research And Biostatistics (US)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-12-21
- DOI
- https://doi.org/10.1080/14796694.2025.2600910
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00